<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466033</url>
  </required_header>
  <id_info>
    <org_study_id>C14-CLN002</org_study_id>
    <nct_id>NCT04466033</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Performance of Magneto Microcatheter</brief_title>
  <official_title>Evaluation of the Safety and Performance of Magneto Microcatheter for Endovascular Thrombectomy in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magneto Thrombectomy Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magneto Thrombectomy Solutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label single arm feasibility study to evaluate the safety and performance
      of the Magneto Microcatheter in patients diagnosed with acute ischemic stroke and planned for
      thrombectomy procedure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the safety of Magneto Microcatheter in the acute post procedure duration by assessing the incidence of device related Serious Adverse Events within 24 hours post procedure</measure>
    <time_frame>24 hours</time_frame>
    <description>Occurrence of device related Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety of Magneto Microcatheter by assessing the incidence of device related Serious Adverse Events within 90 days post procedure</measure>
    <time_frame>90 days</time_frame>
    <description>Occurrence of device related Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the performance of Magneto Microcatheter by assessing its ability to remove the clot and evaluating its ease of use</measure>
    <time_frame>During Procedure</time_frame>
    <description>Assessment of device performance in clot removal (TICI scale to evaluate revascularization) and ease of use (questionnaire that will be completed by the treating physician post procedure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Magneto Microcatheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magneto Microcatheter</intervention_name>
    <description>All patients will be treated with Magneto Microcatheter</description>
    <arm_group_label>Magneto Microcatheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical signs consistent with acute ischemic stroke

          2. Patient with Acute Ischemic Stroke within 24 hours from symptoms o

          3. Age 18-85 years old

          4. Consent process is completed per international and local regulations

        Exclusion Criteria:

          1. Known use of cocaine or other vasoactive substance

          2. Known bleeding diathesis

          3. Any known hemorrhagic or coagulation deficiency.

          4. Current use of oral anticoagulants with International Normalized Ratio (INR) &gt; 3;

          5. PTT (Partial Thromboplastin Time)&gt;2 at screening

          6. Uncontrolled hypertension (Systolic blood pressure&gt;185 or Diastolic blood
             pressure&gt;110) refractory to pharmacological management

          7. Pregnant or lactating female

          8. CT scan or MRI with evidence of acute intracranial hemorrhage, ASPECT score&lt;6, mass
             effect and/or intracranial tumor

          9. Angiographic evidence of either carotid dissection or vasculitis at the target site or
             any condition that may limit device access to the target site (i.e high grade
             stenosis) per the treating physician's discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Marzelik</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.Amsalem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelly Sharon</last_name>
    <phone>0765300768</phone>
    <email>shelly@magts.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 5, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

